The stock of the investment management firm looks as though it could be in for more price weakness.
We have two price target areas for this biopharmaceutical firm.
These recently downgraded names are displaying both quantitative and technical deterioration.
Shares of IFF have improved quickly from its October low.
NKE has made a strong rally from early October without a retest of its low.
Interestingly, TheStreet's Quant Ratings service upgraded its rating on STZ Friday.
As we review Azek, we see why Americans might be building lots of decks this year -- and why this might be a good knock-on trade.
The shares have traded sideways since earlier this year, which is not bad in a bear market for most stocks.
Here are the next targets for this energy name that just posted quarterly earnings, got an upgrade.
Here's what traders looking to go long BG should wait for.